Saturday 17 October 2026
Export DNLI’s income statement to Excel — free account
Denali Therapeutics Inc.
DNLI Healthcare Biotechnology
In the quarter to June 2026, revenue fell 89.7%, EPS grew 5.56%, free cash flow fell 22.9% and total debt fell 1.76%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
17.56
0.78
−4.25%
Follow DNLI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — |
+8 more quarters Free account |
P/S ratio |
16.11 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(49.67) | — | — | — | |
P/B ratio |
5.77 | — | — | — | |
Price to Tangible BV |
6.02 | — | — | — | |
EV/Sales |
13.76 | — | — | — | |
EV/EBITDA |
0.00 | — | — | — | |
EV/Operating CF |
(9.48) | — | — | — | |
EV/FCF |
(9.40) | — | — | — | |
Quick Ratio |
7.93 | 8.97 | 8.82 | 9.41 | |
Current Ratio |
8.37 | 9.28 | 9.16 | 9.79 | |
Net Debt/EBITDA |
5.49 | 7.23 | 6.33 | 6.17 | |
Debt/Assets |
0.47% | 0.44% | 0.48% | 0.53% | |
Debt/Equity |
0.01 | 0.01 | 0.01 | 0.01 | |
Asset Turnover |
0.26 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.76 | 1.02 | 0.77 | 0.85 | |
Capex/Depreciation |
(0.38) | (1.55) | (1.25) | 1.50 | |
Research and Development Expense of Revenue |
2,691.98% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,006.74% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
635.82% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.09 | — | — | — | |
Graham Number |
0.00 | — | — | — | |
Earnings Yield |
(11.04%) | — | — | — | |
Free Cash Flow Yield |
(9.08%) | — | — | — | |
Revenue per Share |
0.02 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.52) | (0.70) | (0.57) | (0.62) | |
Capex per Share |
0.00 | (0.01) | (0.01) | 0.01 | |
Free Cash Flow per Share |
(0.52) | (0.72) | (0.58) | (0.61) | |
Cash per Share |
3.79 | 5.29 | 5.03 | 4.92 | |
Shareholders Equity per Share |
4.46 | 4.96 | 5.87 | 5.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.46 | 4.96 | 5.87 | 5.37 | |
Free Cash Flow |
(97.81) | (133.67) | (100.06) | (105.92) | |
Working Capital |
663.84 | 912.60 | 802.31 | 792.45 | |
Capital Expenditures |
(0.80) | (2.47) | (1.52) | 1.38 | |
Net Current Asset Value |
431.15 | 682.83 | 769.57 | 753.17 | |
EV/EBIT |
0.00 | — | — | — | |
Capex to Sales |
0.22 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Receivables |
1.96 | — | — | — | |
Average Payables |
11.33 | 24.42 | 5.82 | 8.17 | |
Average Assets |
1,162.10 | 1,268.68 | 1,259.52 | 1,254.82 | |
Average Common Equity |
931.12 | 1,024.39 | 1,121.72 | 1,122.35 |
Columns are period end dates